Immune cells in the brain called microglia can partially break down large amyloid plaques characteristic of Alzheimer's ...

Immune cells in the brain called microglia can partially break down large amyloid plaques characteristic of Alzheimer's disease by latching on to ...

Ke Hou generated a compound that prevents tau aggregation in the murine brain, but the potential Alzheimer’s disease therapy ...

Alzheimer’s disease is the most prevalent form of dementia and is primarily characterized by the accumulation of β-amyloid and phosphorylated tau proteins in the brain, along with the degeneration of ...

Transthyretin amyloid cardiomyopathy occurs when TTR tetramers dissociate into misfolded monomers that deposit as myocardium amyloid fibrils. Ex vivo studies found that acoramidis, a high-affinity TTR ...

Light chain amyloidosis is caused by plasma cells in the bone marrow that produce more light chain proteins than heavy chain proteins, which ultimately leads to the deposition of amyloid fibrils ...

They ask regulators to acknowledge four decades of evidence showing that cerebral Aβ aggregation causes Alzheimer’s disease by focusing the licensing approval process squarely on amyloid clearance.

The researchers concluded that active screening for ATTR-CM can identify more women with the disease. ATTR-CM is a disease caused by the accumulation of amyloid fibrils misfolded TTR protein in the ...

in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI ® ” (lecanemab) for the treatment of early Alzheimer’s disease (AD)*. LEQEMBI selectively binds ...